A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices

Invibio Biomaterial Solutions, part of Victrex plc, a pioneer in the development of PEEK biomaterial solutions, today announced a new collaboration with Paragon Medical, a medical device contract design manufacturer with over a century of combined expertise in high-precision manufacturing, advanced engineering and design support, to manufacture composite PEEK-OPTIMA™ Ultra-Reinforced medical trauma devices.

The manufacturing arrangement with Paragon Medical will support the scale up of high quality PEEK-OPTIMA™ ultra-reinforced composite fracture fixation devices, at a time when Invibio is seeing demand exceeding initial expectations.

The announcement coincides with Paragon Medical’s recent expansion of dedicated space for this collaboration in their manufacturing facility in Changzhou, China.

Investing in the future of Invibio PEEK-OPTIMA™ Ultra-Reinforced composite devices

Invibio has extensive experience in collaborating with customers in PEEK-OPTIMA™ Ultra-Reinforced part design and process development, with significant know-how and intellectual property (IP). During this time Invibio has developed novel materials and IP in relation to optimising the design and development of these parts and supporting customers with regulatory approval.

“We are delighted to be working with Invibio to increase production of their innovative devices which can help to drive improved patient outcomes globally,” says Wil Boren, Paragon Medical CEO.

Providing scale, quality, confidence and manufacturing flexibility

The recent opening of the Invibio Leeds orthopedic product development centre in the UK has the potential to support an increase in the speed at which medical device companies can develop new PEEK-OPTIMA™ Ultra-Reinforced composite fracture fixation devices.

The Paragon Medical collaboration can provide Invibio customers with additional world class medical composite manufacturing facilities to help serve growing customer demand for these products.

“Trauma is one of Victrex’s key mega-programmes, where we see significant growth opportunities over the years ahead and the opportunity to enhance patient outcomes. Clinical data on PEEK based trauma plates is already encouraging and initial demand is exceeding our expectations. We have invested over several years now, and bring a wealth of intellectual property in this area. Paragon Medical will help us support manufacturing scale up, and they bring an excellent reputation as one of the world’s premier medical contract manufacturers. We are delighted to work with them to grow the composite trauma space and to make it easier for medical device companies to adopt this technology,” explains Jakob Sigurdsson, CEO of Victrex.

“With a broad operating footprint in Europe, China and America, Paragon Medical are an attractive company to work with, dealing with evolving supply chain strategies within the medical device industry.”

PEEK-OPTIMA™ Ultra-Reinforced composite device benefits

Patient risk factors affecting fracture healing such as diabetes, osteoporosis or obesity have increased significantly in recent years, which has in turn increased the challenges for traditional titanium plates and nails to successfully heal patients. The increased risk of delayed union or non-union may be reduced by utilising plates made from PEEK-OPTIMA™ Ultra-Reinforced materials due to their increased fatigue lifetime and the ability to tailor the stiffness of the device.*

PEEK based medical devices have been successfully implanted for over twenty years. The benefits of PEEK OPTIMA Ultra reinforced trauma plates such as increased fatigue lifetime, tailored stiffness and improved imaging are now being utilised to treat a more challenging patient population.*

The potential to reduce revisions and accelerate healing make these solutions attractive to surgeons, patients and to payors.

SourceInvibio
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy